
AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

